UA86059C2 - Полиморфные формы трет-бутилового эфира аторвастатина и их использование как промежуточных соединений для получения аторвастатина - Google Patents

Полиморфные формы трет-бутилового эфира аторвастатина и их использование как промежуточных соединений для получения аторвастатина

Info

Publication number
UA86059C2
UA86059C2 UAA200610957A UAA200610957A UA86059C2 UA 86059 C2 UA86059 C2 UA 86059C2 UA A200610957 A UAA200610957 A UA A200610957A UA A200610957 A UAA200610957 A UA A200610957A UA 86059 C2 UA86059 C2 UA 86059C2
Authority
UA
Ukraine
Prior art keywords
atorvastatin
preparation
tert
butylester
polymorphs
Prior art date
Application number
UAA200610957A
Other languages
English (en)
Ukrainian (uk)
Inventor
Антон Стимац
Рок Зупет
Мария Грцман
Матей Смрколй
Рената Йаксе
Original Assignee
Крка, Товарна Здравил, Д.Д. Ново Место
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Крка, Товарна Здравил, Д.Д. Ново Место filed Critical Крка, Товарна Здравил, Д.Д. Ново Место
Publication of UA86059C2 publication Critical patent/UA86059C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
UAA200610957A 2004-04-09 2005-08-04 Полиморфные формы трет-бутилового эфира аторвастатина и их использование как промежуточных соединений для получения аторвастатина UA86059C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200400112A SI21745A (sl) 2004-04-09 2004-04-09 Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina

Publications (1)

Publication Number Publication Date
UA86059C2 true UA86059C2 (ru) 2009-03-25

Family

ID=34963800

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200610957A UA86059C2 (ru) 2004-04-09 2005-08-04 Полиморфные формы трет-бутилового эфира аторвастатина и их использование как промежуточных соединений для получения аторвастатина

Country Status (15)

Country Link
EP (1) EP1732886B1 (ru)
CN (2) CN1946687B (ru)
AT (1) ATE459602T1 (ru)
DE (1) DE602005019703D1 (ru)
DK (1) DK1732886T3 (ru)
EA (1) EA010166B1 (ru)
ES (1) ES2339570T3 (ru)
HR (1) HRP20100217T1 (ru)
NO (1) NO20065146L (ru)
PL (1) PL1732886T3 (ru)
PT (1) PT1732886E (ru)
RS (1) RS51259B (ru)
SI (2) SI21745A (ru)
UA (1) UA86059C2 (ru)
WO (1) WO2005097742A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US20100260851A1 (en) * 2007-07-11 2010-10-14 Actavis Group Ptc Ehf Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
US20090081801A1 (en) * 2007-08-15 2009-03-26 Vinod Kumar Kansal Process for synthesis of pyrrole derivative, an intermediate for atorvastatin
CN101560177B (zh) * 2008-04-16 2012-10-03 北京万全阳光医学技术有限公司 一种阿托伐他汀钙的制备方法
EP2413911B1 (en) 2009-03-31 2014-02-19 KRKA, D.D., Novo Mesto Progressive emulsion crystallization
CN105693587A (zh) * 2016-01-15 2016-06-22 安徽悦康凯悦制药有限公司 一种阿托伐他汀钙的生产工艺
CN109280024A (zh) * 2018-10-09 2019-01-29 河南师范大学 一种高纯度阿托伐他汀叔丁酯的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE60136095D1 (de) * 2000-11-16 2008-11-20 Teva Pharma Hydrolyse von är(r*,r*)ü-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-heptansäureestern mit calciumhydroxid
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
CZ2004337A3 (cs) * 2001-08-16 2005-01-12 Teva Pharmaceutical Industries Ltd. Způsob přípravy vápenatých solí statinů

Also Published As

Publication number Publication date
PL1732886T3 (pl) 2010-08-31
SI1732886T1 (sl) 2010-06-30
HRP20100217T1 (hr) 2010-05-31
EP1732886B1 (en) 2010-03-03
PT1732886E (pt) 2010-03-12
ES2339570T3 (es) 2010-05-21
EA010166B1 (ru) 2008-06-30
RS51259B (sr) 2010-12-31
DE602005019703D1 (de) 2010-04-15
DK1732886T3 (da) 2010-06-14
CN1946687B (zh) 2011-09-28
CN101538238A (zh) 2009-09-23
EP1732886A1 (en) 2006-12-20
WO2005097742A1 (en) 2005-10-20
CN1946687A (zh) 2007-04-11
NO20065146L (no) 2006-11-08
EA200601651A1 (ru) 2007-02-27
SI21745A (sl) 2005-10-31
CN101538238B (zh) 2012-08-29
ATE459602T1 (de) 2010-03-15

Similar Documents

Publication Publication Date Title
WO2007058583A3 (en) Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
TW200734311A (en) New compounds
UA86059C2 (ru) Полиморфные формы трет-бутилового эфира аторвастатина и их использование как промежуточных соединений для получения аторвастатина
MY147390A (en) Substituted isoindoles as bace inhibitors and their use
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
WO2006041405A1 (en) Substituted amino-pyrimidones and uses thereof
WO2005062897A3 (en) Polymorphs of ezetimibe and processes for the preparation thereof
EP1416933B8 (en) Substituted piperidines as modulators of the melanocortin receptor
WO2003086306A3 (en) 5ht2c receptor modulators
TW200716558A (en) Heteroaroyl-substituted serineamides
WO2005070891A3 (en) Compounds and methods of use
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
UA93531C2 (en) Novel hydrogen sulfate salt
WO2005075467A3 (en) Crystalline forms of zolmitriptan
TNSN07165A1 (en) Organic compounds
TW200635905A (en) Processes for producing 4-aminoquinazolines
AU2003293746A1 (en) Crystalline cefdinir salts
WO2006075139A3 (en) Novel process for the preparation of substituted indoles
MXPA03012045A (es) Proceso para preparar derivados del acido 7-amino sin 3,5-dihidroxi heptanoico a traves de derivados del acido 6-ciano sin 3,5-dihidroxi hexanoico.
TW200621223A (en) Acyclic 1,3-diamines and uses therefor
WO2008059519A3 (en) A process for the preparation of intermediates of rosuvastatin
IL183271A0 (en) Crystalline form of cefdinir ammonium salt as an intermediate for the preparation of pure cefdinir
WO2008059513A3 (en) Compounds suitable as modulators of hdl
WO2006110185A3 (en) Antiinfective lipopeptides
WO2006018807A8 (en) Crystalline forms of cefdinir